Search hospitals > Missouri > Farmington
Parkland Health Center - Farmington
Claim this profileFarmington, Missouri 63640
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
164 reported clinical trials
1 medical researcher
Summary
Parkland Health Center - Farmington is a medical facility located in Farmington, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Parkland Health Center - Farmington is involved with conducting 164 clinical trials across 314 conditions. There are 1 research doctors associated with this hospital, such as Bryan A. Faller.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Clinical Trials running at Parkland Health Center - Farmington
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Gastric Cancer
Renal Cell Carcinoma
Bladder Carcinoma
Gastroesophageal Junction Adenocarcinoma
Gallbladder Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Parkland Health Center - Farmington?
Parkland Health Center - Farmington is a medical facility located in Farmington, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Parkland Health Center - Farmington is involved with conducting 164 clinical trials across 314 conditions. There are 1 research doctors associated with this hospital, such as Bryan A. Faller.